



## APPENDIX B

CLAIMS PENDING IN USSN 09/396,985.

38. A method of screening for modulators of a lipopolysaccharide mediated response comprising the steps of:

- a) obtaining a TLR-4 polypeptide;
- b) measuring a lipopolysaccharide mediated response mediated by the TLR-4 polypeptide;
- c) contacting the TLR-4 polypeptide with a putative modulator;
- d) assaying for a change in the lipopolysaccharide mediated response; and
- e) comparing the lipopolysaccharide mediated responses mediated by the TLR-4 polypeptide obtained in steps b) and d) above

wherein a difference in the lipopolysaccharide mediated responses indicates that the putative modulator is a modulator of a lipopolysaccharide mediated response.

39. The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99.

40. The method of claim 39, wherein the lipopolysaccharide mediated response is determined by determining the ability of the TLR-4 polypeptide to stimulate transcription of a reporter gene, the reporter gene comprising a nucleic acid segment comprising a promoter and a reporter gene, wherein the reporter gene is a control gene.

52. The method of claim 38, wherein the lipopolysaccharide mediated response is determined by determining the ability of the TLR-4 polypeptide to stimulate transcription of a reporter gene, the reporter gene comprising a nucleic acid segment comprising a promoter and a reporter gene, wherein the reporter gene is a control gene.

53. The method of claim 52, wherein said putative modulator is an agonist.
54. The method of claim 52, wherein said putative modulator is an antagonist.
55. The method of claim 52, wherein said putative modulator affects the transcription of TLR-4.
56. The method of claim 52, wherein said putative modulator affects the translation of TLR-4.
57. The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:2.
58. The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:4.
59. The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:6.
60. The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:98.
61. The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:99.
63. The method of claim 38, wherein said putative modulator inhibits TLR-4 directed signaling of TNF secretion.
64. The method of claim 38, wherein said putative modulator stimulates TLR-4 directed signaling of TNF secretion.

65. The method of claim 38, wherein said putative modulator to be screened is obtained from a library of synthetic chemicals.
66. The method of claim 38, wherein said putative modulator to be screened is obtained from a natural source.
67. The method of claim 65, wherein said natural source is selected from the group consisting of animals, bacteria, fungi, plant sources and living marine samples.
68. The method of claim 38, wherein said putative modulator to be screened is a protein or peptide.
70. The method of claim 38, wherein said putative modulator to be screened is a nucleic acid molecule.
71. The method of claim 38, wherein said putative modulator to be screened is a stimulator of an immune response.
72. The method of claim 71, wherein said stimulator of an immune response is a cytokine.
73. The method of claim 71, wherein said stimulator of an immune response is an interferon.
74. The method of claim 38, wherein said TLR-4 polypeptide is encoded by a nucleic acid sequence selected from the group comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48.
75. The method of claim 38, wherein said putative modulator to be screened is an IL-1 receptor antagonist.

100. The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence selected from the group comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 and SEQ ID NO:99.

101. The method of claim 38, wherein said putative modulator to be screened is a small molecule.

102. The method of claim 101, wherein said small molecule inhibits TLR-4 mediation of the lipopolysaccharide mediated response.

103. The method of claim 101, wherein said small molecule inhibits the lipopolysaccharide mediated response.